Adaptimmune Therapeutics ADAP Stock
Adaptimmune Therapeutics Price Chart
Adaptimmune Therapeutics ADAP Financial and Trading Overview
| Adaptimmune Therapeutics stock price | 0.05 USD |
| Previous Close | 0 USD |
| Open | 0.07 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.05 - 0.05 USD |
| 52 Week Range | 0.02 - 0.86 USD |
| Volume | 48.74M USD |
| Avg. Volume | 110.64M USD |
| Market Cap | 14.55M USD |
| Beta (5Y Monthly) | 2.492 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.68 USD |
ADAP Valuation Measures
| Enterprise Value | 108.34M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.14447369 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.2235743 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 1.665 |
| Enterprise Value/EBITDA | -0.789 |
Trading Information
Adaptimmune Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.492 |
| 52-Week Change | -93.93% |
| S&P500 52-Week Change | 19.73% |
| 52 Week High | 0.86 USD |
| 52 Week Low | 0.02 USD |
| 50-Day Moving Average | 0.1 USD |
| 200-Day Moving Average | 0.26 USD |
ADAP Share Statistics
| Avg. Volume (3 month) | 110.64M USD |
| Avg. Daily Volume (10-Days) | 115.54M USD |
| Shares Outstanding | 265.05M |
| Float | 1.22B |
| Short Ratio | 0.19 |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 31.23% |
| Shares Short | 31.38M |
| Short % of Float | 14.33% |
| Short % of Shares Outstanding | 11.83% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | -260.82% |
| Operating Margin (ttm) | -221.45% |
| Gross Margin | -97.72% |
| EBITDA Margin | -210.86% |
Management Effectiveness
| Return on Assets (ttm) | -40.86% |
| Return on Equity (ttm) | -1341.097% |
Income Statement
| Revenue (ttm) | 65.09M USD |
| Revenue Per Share (ttm) | 0.25 USD |
| Quarterly Revenue Growth (yoy) | -89.29% |
| Gross Profit (ttm) | -63606000 USD |
| EBITDA | -137240992 USD |
| Net Income Avi to Common (ttm) | -169756000 USD |
| Diluted EPS (ttm) | -0.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 26.06M USD |
| Total Cash Per Share (mrq) | 0.02 USD |
| Total Debt (mrq) | 48.68M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.516 |
| Book Value Per Share (mrq) | -0.268 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -190027008 USD |
| Levered Free Cash Flow (ttm) | -123189752 USD |
Profile of Adaptimmune Therapeutics
| Country | United States |
| State | N/A |
| City | Abingdon |
| Address | 60 Jubilee Avenue |
| ZIP | OX14 4RX |
| Phone | 44 12 3543 0000 |
| Website | https://www.adaptimmune.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 506 |
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Q&A For Adaptimmune Therapeutics Stock
What is a current ADAP stock price?
Adaptimmune Therapeutics ADAP stock price today per share is 0.05 USD.
How to purchase Adaptimmune Therapeutics stock?
You can buy ADAP shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adaptimmune Therapeutics?
The stock symbol or ticker of Adaptimmune Therapeutics is ADAP.
Which industry does the Adaptimmune Therapeutics company belong to?
The Adaptimmune Therapeutics industry is Biotechnology.
How many shares does Adaptimmune Therapeutics have in circulation?
The max supply of Adaptimmune Therapeutics shares is 265.05M.
What is Adaptimmune Therapeutics Price to Earnings Ratio (PE Ratio)?
Adaptimmune Therapeutics PE Ratio is 0.00000000 now.
What was Adaptimmune Therapeutics earnings per share over the trailing 12 months (TTM)?
Adaptimmune Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Adaptimmune Therapeutics company belong to?
The Adaptimmune Therapeutics sector is Healthcare.
Adaptimmune Therapeutics ADAP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 22078.05 USD — |
-2.15
|
8.98B USD — | 22043.2 USD — | 23147.33 USD — | — - | 8.98B USD — |
| US Tech Composite Total Return XCMP | 27130 USD — |
-2.13
|
— — | 27087.19 USD — | 28443.68 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 10828.86 USD — |
-2.16
|
— — | 10811.1 USD — | 11352.37 USD — | — - | — — |
| US Tech Biotechnology NBI | 5507.99 USD — |
-0.91
|
— — | 5504.93 USD — | 5663.87 USD — | — - | — — |
| US Tech Health Care IXHC | 1144.38 USD — |
-0.91
|
— — | 1143.94 USD — | 1175.72 USD — | — - | — — |
- {{ link.label }} {{link}}